AAA announces first patients dosed in 2 clinical studies with PSMA-R2 for prostate cancer
Saint-Genis-Pouilly, France, June 22, 2018 - Advanced Accelerator Applications S.A. (AAA), a Novartis company and leader in nuclear medicine theragnostics, today announced that the first...








